An interventional study of denosumab and placebo in Rheumatoid Arthritis, sponsored by Daiichi Sankyo. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-02-12.
Sponsored by Daiichi Sankyo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Arthritis, Rheumatoid with a site in Japan — 9 open to participants now, 12 under way, 2 of them phase 3. Arthritis, Rheumatoid · Japan.
Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, this one is the 21st largest by enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2013, is the only one with no phase, and was the 84th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 153 studies in Arthritis, Rheumatoid with a site in Japan are open now. Recruiting first, the newest first:
AbbVie · Sites in Japan, United States
Ages 18–75
Merck Sharp & Dohme LLC · Sites in Japan, Australia, Belgium and 8 more countries
Ages 18–75
GlaxoSmithKline · Sites in Japan, Argentina, Brazil and 6 more countries
Ages 18–70
Eli Lilly and Company · Sites in Japan, Australia, China
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in Japan, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 43 · Phase 3 69 · Phase 4 10
First in 2003; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 679 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 265 across the 132 interventional studies, 505 across the 21 observational. Of the 131 that completed or were terminated, 92 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 153 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
Daiichi Sankyo has 4 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05966519Zimmer BiometROSA Knee Intraoperative Planning Flexibility Study | 2027-01 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously to rheumatoid arthritis participants.
To evaluate the inhibitory effect of progression, compared with placebo, in joint destruction by AMG 162 administered subcutaneously at a dose of 60 mg every 6 months or every 3 months for 12 months to rheumatoid arthritis participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
denosumab administered subcutaneously every 6 months
Drug: denosumab
denosumab administered subcutaneously every 3 months
Drug: denosumab
placebo administered subcutaneously to match denosumab
Drug: placebo
denosumab administered subcutaneously
Also known as: AMG 162
placebo administered subcutaneously to match denosumab
Change in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Total Sharp Score (TSS) from baseline to month 12 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.
Time frame: baseline to month 12
Change in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Total Sharp Score (TSS) from baseline to month 6 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.
Time frame: baseline to month 6
Change in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Erosion Score from baseline to month 6 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.
Time frame: baseline to month 6
Change in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Joint Space Narrowing from baseline to month 6 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.
Time frame: baseline to month 6
Change in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Erosion Score from baseline to month 12 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.
Time frame: baseline to month 12
Change in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
Change from baseline in Joint Space Narrowing from baseline to month 12 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.
Time frame: baseline to month 12
Percent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo
The percent change from baseline in Bone Mineral Density (BMD) to month 12 was assessed. Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA).
Time frame: baseline to month 12
A total of 679 participants who met all inclusion and none of the exclusion criteria were included in the study; efficacy outcomes were assessed in the Full Analysis Set (n=654).
| Milestone | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Started | 228 | 225 | 226 |
| Received study drug | 222 | 222 | 223 |
| Did not receive study drug | 6 | 3 | 3 |
| Discontinued study treatment | 23 | 22 | 15 |
| Discontinued study | 23 | 22 | 15 |
| Completed | 199 | 200 | 208 |
| Not completed | 29 | 25 | 18 |
| Withdrew: Adverse event | 9 | 2 | 4 |
| Withdrew: Protocol violation | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 7 | 5 | 2 |
| Withdrew: Invasive dental treatment | 3 | 5 | 6 |
| Withdrew: Prohibited concomitant d | 1 | 5 | 0 |
| Withdrew: Disease progression | 0 | 3 | 0 |
| Withdrew: Other | 1 | 1 | 0 |
| Withdrew: Did not receive study drug | 6 | 3 | 3 |
Change from baseline in Total Sharp Score (TSS) from baseline to month 12 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Total Sharp Score (TSS) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo | 0.99 (0.49 to 1.49) | 0.72 (0.41 to 1.03) | 1.49 (0.99 to 1.99) |
Change from baseline in Total Sharp Score (TSS) from baseline to month 6 was assessed. The TSS was defined as the sum of the erosion score and the joint space narrowing scores from radiographic assessments. The maximum radiographic TSS from the both hands/wrists and both feet is 448. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Total Sharp Score (TSS) From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo | 0.62 (0.27 to 0.98) | 0.48 (0.24 to 0.72) | 0.92 (0.60 to 1.23) |
Change from baseline in Erosion Score from baseline to month 6 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Erosion Score From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo | 0.34 (0.16 to 0.53) | 0.13 (0.03 to 0.24) | 0.58 (0.39 to 0.78) |
Change from baseline in Joint Space Narrowing from baseline to month 6 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Joint Space Narrowing From Baseline to Month 6 Following Subcutaneous Administration of Denosumab or Placebo | 0.28 (0.07 to 0.50) | 0.35 (0.17 to 0.53) | 0.33 (0.18 to 0.48) |
Change from baseline in Erosion Score from baseline to month 12 was assessed. The Erosion Score was defined for the sum of the joint level erosion scores among the 44 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Erosion Score from both hands/wrist and both feet is 280. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Erosion Score From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo | 0.51 (0.22 to 0.80) | 0.22 (0.09 to 0.34) | 0.98 (0.65 to 1.31) |
Change from baseline in Joint Space Narrowing from baseline to month 12 was assessed. Joint Space Narrowing was defined for the sum of the joint level joint space narrowing scores among the 42 joints in both hands/wrist and both feet from radiographic assessments using the van der Heijde modified Sharp scoring method. The maximum radiographic Joint Space Narrowing from both hands/wrists and both feet is 168. Higher values represented greater damage.
| score on a scale | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Change in Joint Space Narrowing From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo | 0.48 (0.20 to 0.76) | 0.50 (0.27 to 0.74) | 0.51 (0.28 to 0.74) |
The percent change from baseline in Bone Mineral Density (BMD) to month 12 was assessed. Bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA).
| percent change | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Percent Change in Bone Mineral Density (BMD) From Baseline to Month 12 Following Subcutaneous Administration of Denosumab or Placebo | 3.99 ± 0.24 | 4.88 ± 0.24 | -1.03 ± 0.25 |
Collected over Adverse event data were collected from the first dose to the last dose of study drug, up to 12 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 6 Months | 0/221 (0%) | 19/221 (8.6%) | 127/221 (57.5%) |
| Denosumab 3 Months | 1/222 (0.5%) | 19/222 (8.6%) | 122/222 (55%) |
| Placebo | 0/224 (0%) | 13/224 (5.8%) | 125/224 (55.8%) |
| Event | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| Benign prostatic hyperplasiaReproductive system and breast disorders | 2/221 | 0/222 | 0/224 |
| Immune thrombocytopenic purpuraBlood and lymphatic system disorders | 1/221 | 0/222 | 0/224 |
| EnterocolitisGastrointestinal disorders | 1/221 | 0/222 | 0/224 |
| Abscess jawInfections and infestations | 1/221 | 0/222 | 0/224 |
| Pyelonephritis acuteInfections and infestations | 1/221 | 0/222 | 0/224 |
| SepsisInfections and infestations | 1/221 | 0/222 | 0/224 |
| TuberculosisInfections and infestations | 1/221 | 0/222 | 0/224 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/221 | 0/222 | 0/224 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/221 | 0/222 | 0/224 |
| SynovitisMusculoskeletal and connective tissue disorders | 1/221 | 0/222 | 0/224 |
| Event | Denosumab 6 Months | Denosumab 3 Months | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 79/221 | 69/222 | 73/224 |
| StomatitisGastrointestinal disorders | 22/221 | 27/222 | 13/224 |
| Hepatic function abnormalHepatobiliary disorders | 14/221 | 13/222 | 20/224 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 18/221 | 8/222 | 9/224 |
| PharyngitisInfections and infestations | 13/221 | 16/222 | 16/224 |
| Dental cariesGastrointestinal disorders | 12/221 | 7/222 | 9/224 |
| Back painMusculoskeletal and connective tissue disorders | 5/221 | 12/222 | 7/224 |
| InfluenzaInfections and infestations | 8/221 | 10/222 | 12/224 |
The Baseline Analysis Population included participants in the Full Analysis Set (FAS). The FAS was defined as all randomized participants excluding those who met any of the following criteria: * Received no investigational product * Had no baseline TSS or no available TSS after the first administration of the investigational product
| Age, Categorical(Participants) | Denosumab 6 Months | Denosumab 3 Months | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 140 | 150 | 163 | 453 |
| >=65 years | 77 | 69 | 55 | 201 |
| Age, Continuous(years) | Denosumab 6 Months | Denosumab 3 Months | Placebo | Total |
|---|---|---|---|---|
| Mean | 58.1 ± 12.3 | 58.2 ± 12.04 | 55.8 ± 11.7 | 57.4 ± 12.04 |
| Sex: Female, Male(Participants) | Denosumab 6 Months | Denosumab 3 Months | Placebo | Total |
|---|---|---|---|---|
| Female | 168 | 154 | 167 | 489 |
| Male | 49 | 65 | 51 | 165 |
| Region of Enrollment(participants) | Denosumab 6 Months | Denosumab 3 Months | Placebo | Total |
|---|---|---|---|---|
| Japan | 217 | 219 | 218 | 654 |
| Body mass index (BMI)(kg/m^2) | Denosumab 6 Months | Denosumab 3 Months | Placebo | Total |
|---|---|---|---|---|
| Mean | 22.38 ± 3.68 | 22.64 ± 3.62 | 22.65 ± 3.49 | 22.56 ± 3.59 |
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https:// vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Oct 2013 to primary completion in Dec 2015, 26 months.
Results were first posted in Dec 2019, 4 years after primary completion.
Of 56 industry-sponsored interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 92. This study's 26 months is below that.
Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab